Acumen Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview

Acumen Pharmaceuticals

25/03/2025 12:39

Acumen Pharmaceuticals Inc ABOS.OQ ABOS.O is expected to show no change in quarterly revenue when it reports  results on March 27 for the period ending December 31 2024

​LSEG's mean analyst estimate for Acumen Pharmaceuticals Inc is for a loss of 48 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $11.00​, above​ its last closing price of $1.24. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.41
-0.36
-0.50
Missed
-37
Jun. 30 2024
-0.28
-0.28
-0.34
Missed
-21.4
Mar. 31 2024
-0.26
-0.26
-0.25
Beat
3.8​
Dec. 31 2023
-0.30
-0.26
-0.28
Missed
-7.7
​​Sep. 30 2023
-0.27
-0.27
-0.24
Beat
9.8
Jun. 30 2023
-0.34
-0.35
-0.28
Beat
19.1​
Mar. 31 2023
-0.35
-0.35
-0.28
Beat
19.1
Dec. 31 2022
-0.26
-0.32
Missed
-25.3

This summary was machine generated March 25 at 12:39 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)